

# innoV<sup>itro</sup>

<i>Name</i>	<b>innoV<sup>itro</sup> GmbH</b>
<i>Address</i>	Artilleriestraße 2
<i>Postal Code / City</i>	52428 Jülich · Germany
<i>Contact Person</i>	Dr. Matthias Goßmann
<i>Phone</i>	+49 2461 317 056 13
<i>E-Mail</i>	<a href="mailto:gossmann@innovitro.de">gossmann@innovitro.de</a>
<i>Website</i>	<a href="http://www.innovitro.de">www.innovitro.de</a>
<i>Employees</i>	4
<i>Founded</i>	2018

---

innoV<sup>itro</sup> GmbH is a preclinical contract research organization providing human cardiac risk and efficacy testing services to pharmaceutical, biotech and academic companies worldwide. Each service is customized by a team of experts in close collaboration with the client and delivered as an end-to-end study report in less than 6 weeks. Screening parameters include structural and functional endpoints of human iPSC-derived cardiomyocytes analyzed using a high-throughput 96-well hybrid system. Drug-induced changes in healthy or diseased cells can be assessed in terms of cellular and electrophysiological properties (CardioExcyte module) as well as changes in contractility (FLEXcyte 96 module). This enables the analysis of the contractility of mature cardiomyocytes through flexible membranes that mimic the in vivo conditions of the human heart.